Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer
ConclusionEntinostat with exemestane showed reasonable safety, tolerability, and encouraging efficacy in Chinese patients with HR+/HER2 − MBC. These results support further evaluation in a randomized, double-blind Phase III study with a weekly 5 mg entinostat dose in a Chinese population.Trial RegistrationNCT02833155.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Anemia | Breast Cancer | Cancer | Cancer & Oncology | China Health | Clinical Trials | HER2 | Hormones | Study | Thrombocytopenia | Toxicology | Ventricular Tachycardia | Women